2020 AABB Annual Meeting On-Demand

Oct 3, 2020 ‐ Oct 3, 2020



Access to the 2020 AABB Annual Meeting On-Demand sessions expires on December 31, 2022. Each session includes the on-demand recording and a downloadable MP3 audio file. Presentation handouts are not available/included.

Planning Committee Disclosures


Sessions

AM20-01: The Impact on the Blood Supply of the Historic Mistrust of the Medical Establishment Among the African American Community

Oct 3, 2020 10:00am ‐ Oct 3, 2020 11:00am

Credits: None available.

Historical events and perceptions have fostered mistrust of the medical community among African Americans, which extends to blood donation. African American blood donation rates have been 25-50% lower than that of the white individuals over the last decade. Although this issue has been repeatedly identified, efforts to address the underlying causes of this disparity have not been examined holistically.

Sickle cell disease (SCD) continues to disproportionally impact the African American community occurring in about 1 out of every 365 births (1 in 13 African American babies are born with the sickle cell trait). Although the transfusion needs of patients with sickle cell disease can be met by blood donors of any ethnicity, the best blood product match is from a phenotype-matched donor of the same ethnic group. When there is increased inventory of blood from African American donors, there is a greater likelihood that a phenotype match will be found. Tackling this important issue requires education and guidance to blood collectors to assist them with developing culturally appropriate and compelling community engagement, recruiting, educational materials and an understanding of the need to reach people where they live.

Agenda:

  • Dr. Yvette Miller, American Red Cross
    Opening Overview
  • Dr. Wayne A. I. Frederick, President, Howard University
    Unique perspective of an individual living with SCD.
  • Dr. Kim Smith-Whitley, University of Pennsylvania School of Medicine, Children’s Hospital of Philadelphia
    Unique challenges of treating children who live with SCD from a transfusion and blood supply perspective.
  • Dr. Carla Williams, Howard University
    Discuss identifying engagement strategies for various communities.
  • Q&A

Speaker(s): Disclosures
  • Wayne Frederick, MD, MBA, FACS : Board Member: Humana & Forma Therateutics
  • Yvette Miller, MD : Nothing to disclose
  • Kim Smith-Whitley, Professor : Consultant: Pfeizer, Global Blood Therapeutics
  • Carla Williams, PhD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-02: Recent Advances in the Practice of Pediatric Transfusion Medicine

Oct 3, 2020 10:00am ‐ Oct 3, 2020 11:00am

Credits: None available.

New literature to help establish evidence-based practice in pediatric transfusion medicine was just published. The Pediatric Critical Care Transfusion and Anemia Expertise Initiative (TAXI) recently published guidelines to direct red blood cell (RBC) transfusion decision making in critically ill children. Similarly, a recent trial looked at outcomes of neonates receiving platelet transfusions at a threshold of 25x109/L. Lastly, the safety of pathogen reduced platelets in the pediatric population, especially neonates, is area of concern which was recently addressed. The session will review these new publications and provide recommendations for pediatric transfusion medicine practice in the areas of RBC transfusions, platelets transfusions and the considerations for the use of pathogen reduced platelets in this unique population.

Learning Objectives:
  • Interpret the recent RBC transfusion guidelines published by the Pediatric Critical Care Transfusion and Anemia Expertise Initiative (TAXI).
  • Incorporate platelet transfusion guidelines for neonates into the transfusion service practice.
  • Assess the use & safety of pathogen reduced platelets in the pediatric population.
Speaker(s): Disclosures
  • Meghan Delaney, DO, MPH : Grant/research Support: Terumo BCT
  • Simon Stanworth, MA, FRCP (Paeds, UK), PhD, FRCPath : Nothing to disclose
  • Marianne Nellis, MD, M.S. : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-03: iPSCs for the Treatment of Beta Hemoglobinopathies

Oct 3, 2020 10:00am ‐ Oct 3, 2020 11:00am

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

Induced pluripotent stem cells (iPSCs), derived from adult cells, have the potential to form any cell type in the body. iPSCs are promising research tools for studying human development, modeling disease and potentially treating patients. Hemoglobinopathies such as sickle cell disease (SCD) and beta thalassemia (BT) are treated with a limited number of pharmacologic options and blood transfusions. The only curative treatment modality is allogeneic transplantation and autologous transplantation with hematopoietic progenitor cell (HPC)-based gene therapy but these approaches have limitations and the latter is still in clinical trials. HPC-based approaches require obtaining sufficient numbers of HPCs via a bone marrow harvest or peripheral blood stem cell collection and maintaining the HPCs ex vivo for more than a short period of time for ex vivo manipulation without a loss of engraftment ability which are challenging to do. iPSCs may offer potential benefits over HPC-based approaches. This session will provide information on the current state of iPSCs for the treatment of hemoglobinopathies.

Learning Objectives:
  • Discuss the role of iPSCs for drug screening and disease modeling
  • Discuss erythroid cell generation from iPSCs obtained from individuals without hemoglobinopathies and their potential clinical applications
  • Discuss cell and gene therapy for beta hemoglobinopathies with iPSCs
Speaker(s): Disclosures
  • Eric Bouhassira, PhD : Nothing to disclose
  • Selami Demirci, PhD : Nothing to disclose
  • George Murphy, PhD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-04: Essential Twitter for Blood Banking and Cellular Therapy Professionals

Oct 3, 2020 11:15am ‐ Oct 3, 2020 12:15pm

Credits: None available.

Using specific examples, we will begin by discussing personal versus professional use of social media. Next, we will discuss different examples of how educational content (#blooducation) is presented on social media including Twitter Chats and articles, paving the way for inclusive conversations on blood banking and cellular therapy topics. Then, in small groups, we will apply these skills in a friendly competition for the title of “Best Tweetorial” as judged by some of AABB’s social media celebrities.

At the end of the session, we hope that you will take away new technical skills and an increased level of confidence to participate in our upcoming AABB Twitter Chats (#AABBPEPTalk) or journal clubs (#AABBjc), as well as share your own professional experiences, insights and knowledge on Twitter from the bench or beyond.

Learning Objectives:
  • contrast personal and professional use of social media
  • design educational content for engagement within a professional learning network
  • identify ways to promote social media engagement as well as digital literacy
  • use Twitter professionally to participate in future social media conversations (e.g., #AABBPEPtalk, #AABBjc)
Speaker(s):
  • Dr. Daniela Hermelin, MD, Assistant Professor of Pathology, Director of Therapeutic Apheresis and Associate Director of Transfusion Medicine, St. Louis University School of Medicine
  • Dr. Justin D. Kreuter, M.D., Consultant and Instructor, Laboratory Medicine and Pathology, Mayo Clinic
  • Aaron Shmookler, MD, Medical Director of Transfusion Services, WVU Medicine
Disclosures
  • Daniela Hermelin, MD : Nothing to disclose
  • Justin Kreuter, M.D. : Nothing to disclose
  • Aaron Shmookler, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-05: Setting the Standard for Transfusion Safety: One Center's Experience Achieving Patient Based Hemovigilance

Oct 3, 2020 11:15am ‐ Oct 3, 2020 12:15pm

Credits: None available.

Transfusion, the most common inpatient procedure, carries risk of adverse events resulting in significant morbidity and mortality. Studies note that the passive reporting system in the United States underreport transfusion reaction rates and only produces population based data. Digitally enabled real time hemovigilance by a team of transfusion specialists allows surveillance for reactions during administration of blood products in our institution. This strategy improves transfusion reaction identification and reporting; it also provides rapid intervention for patients as well as robust data on transfusion reactions. 

Our institution transfuses over 192,000 blood components annually. We built a digital health platform that extracts data from the electronic health record (e.g. increase in temperature, drop in blood pressure) and applies a weighted risk score to each patient receiving transfusion based on an algorithm utilizing the Centers for Disease Control hemovigilance protocol. The risk score prioritizes patients for real time chart reviews by transfusion specialist nurses. If a reaction is suspected, the team deploys an advanced practice provider (e.g. nurse practitioner) to evaluate and manage the patient. All touchpoints in this system are captured as discrete data fields for analysis. Using these data, we are building an artificial intelligence powered human/machine hybrid to aid in detecting transfusion reactions that could be implemented in other organizations. Our analyses currently include over 50,000 transfusions. Operationalizing this clinical program was achieved through collaboration between laboratory and nursing. 

A patient based surveillance program can improve care beyond transfusion reactions if applied to sepsis early identification with rapid response or patient deterioration management. Our strategy has allowed a comprehensive and catalogued review of the transfusion process in our institution, which allows insight into transfusion practice.

Learning Objectives:
  • Differentiate the difference between population based and patient based hemovigilance practices
  • Discuss the advantage that collaboration with nursing brings to laboratory initiated patient surveillance programs and outline the process of educating and establishing transfusion specialized nurses and nurse practitioners
  • Discuss the critical role that digital health plays in accomplishing patient based surveillance
  • Describe how patient specific transfusion reaction risk score based on patient specific data and CDC transfusion reaction definitions is computed and utilized in real time
  • Gather awareness on findings revealed from curation and analysis of over 50,000 transfusions
Speaker(s): Disclosures
  • Tonita Bates, FNP-C : Nothing to disclose
  • Marah Cornelius, FNP-C : Nothing to disclose
  • Leah Murphy, BSN, RN, OCN : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-06: Cellular Therapies for SARS-CoV2

Oct 3, 2020 11:15am ‐ Oct 3, 2020 12:15pm

Credits: None available.

Join us as we review the latest cellular therapy advancements for treatment in the COVID-19 pandemic. In addition to addressing the use of specific T cells in COVID-19 treatment, faculty will also discuss the importance of missing imputation for single cell sequencing (MISC) in COVID-19 analysis.

Learning Objectives:
  • Discuss the latest cellular therapies advancements in the COVID-19 pandemic
  • Investigate the use of specific T cells in COVID-19 treatment
  • Discuss the importance of missing imputation for single cell sequencing (MISC) in COVID-19 analysis
Speaker(s): Disclosures
  • Dusan Bogunovic : Nothing to disclose
  • Michael Keller : Consultant: Gilead
Standard: $25.00
Members: $20.00

AM20-07: Wizardry School of Antigens and Antibodies

Oct 3, 2020 2:30pm ‐ Oct 3, 2020 3:30pm

Credits: None available.

AABB’s Wizardry School of Antigens and Antibodies is back for its fifth year classes. Medical Laboratory Scientists/Technologists and physicians will be challenged to demonstrate their blood bank wizarding skills in interactive case studies. 

Students will be presented with pretransfusion/prenatal test scenarios to practice their antibody identification magic, receive problem solving approaches from Wizardry School faculty, and learn serologic practices from fellow blood bank professionals as all witches and wizards are encouraged to share their spells and potions using interactive audience response. “Graduate” from the fifth school year with new and/or refreshed serological knowledge.

Learning Objectives:
  • Discover how others approach serological testing problems.
  • Utilize efficient and reliable processes for problem resolution.
  • Describe the latest information on serological testing.
Speaker(s): Disclosures
  • Rebecca Coward, MT(ASCP)SBB : Nothing to disclose
  • Monica Kalvelage, MT(ASCP)MB,SBB : Nothing to disclose
  • Jayanna Slayten, MS, MT(ASCP)SBBcm : Honoraria: Immucor
Standard: $25.00
Members: $20.00

AM20-08: Assessment of Anemia Tolerance to Guide Transfusion Decision Making

Oct 3, 2020 2:30pm ‐ Oct 3, 2020 3:30pm

Credits: None available.

Oxygen (O2) homeostasis is critically intertwined with erythropoietic response in blood loss and anemia and the hormones that modulate iron mobilization and RBC production are intriguing markers for the monitoring of transfusion effectiveness in acute and chronic settings. Further, minimally invasive O2 measurements offer a greater understanding of tissue specific adaptation to anemia and response to transfusion. The speakers will guide the audience through physiological adaptive responses to anemia, novel modalities to assess oxygen hemostasis and imbalance and considerations for clinically feasible application toward optimizing transfusion efficacy.

Learning Objectives:
  • Explain the basic science that defines red blood cell communication and tissue adaptive response to hypoxia during anemia.
  • Discuss novel technologies that are adaptable to the assessment of tissue oxygenation pre- and post-transfusion.
  • Differentiate clinically useful approaches to assessing oxygen homeostasis toward guiding transfusion needs during anemia.
Speaker(s): Disclosures
  • Paul Buehler, Pharmd, PhD : Consultant: Kalocyte Inc.
  • Allan Doctor, MD : Stockholder: KaloCyte Inc.; Grant/research Support: KaolCyte Inc.
  • Walter Dzik : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-09: From ABO Blood Group Determination to Immune Tolerance Induction: What Is the Role of the Human Gut Microbiome?

Oct 3, 2020 2:30pm ‐ Oct 3, 2020 3:30pm

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

The session will review the current understanding of the role of the intestinal microbiota in modeling the ABO phenotype and some important immune functions. Microorganisms from the gut flora may produce enzymes such as glycosidases that cleave the A and B antigens which could be applied to convert to type O blood. Gut microflora may also have important function in modulating the immune system and determine patient outcome during organ and cell transplantation rejection and/or graft versus host disease.

Learning Objectives:
  • Review current graft engineering strategies to promote immune tolerance following hematopoietic stem cell transplantation
  • Review the latest developments on the understanding of the role of the intestinal microbiome in immune tolerance induction
  • Review the latest research development in the role of the diversity of intestinal microbiome in preventing graft versus host disease following hematopoietic stem cell transplantation
Speaker(s): Disclosures
  • Jonathan Bromberg, MD, PhD : Grant/Research Support: CareEx, Natera, Estellas, Angion
  • Marcel Van Den Brink, MD, PhD : Research/Grant Support: Seres; Honorarium: Evelo, Seres, Jazz Pharmaceuticals, Therkos, Amgen, Merck & Co, Magenta Therapeutics, WindMIL Therapeutics, Rheos; Royalties: Wolters Kluwer; Stokholder: Seres; IP Licensing: Seres, Juno
  • Albert Yeh, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-10: Vector Borne Pathogens in Transfusion Medicine

Oct 3, 2020 3:45pm ‐ Oct 3, 2020 4:45pm

Credits: None available.

What is new about this topic: We will identify and discuss some emerging and under-studied pathogens and their potential impacts on transfusion medicine and blood banking. We will look at factors that might help blood operators move on from a decreasing threat. 

Background: Emerging pathogens are infectious diseases which newly appear in a population or previously existed but now have an increased incidence or wider geographic range. As climate change continues and vector distributions change, blood operators will need to respond to changing risks of infections in donor populations. In other scenarios, new agents may arise and expand and then regress or “submerge” to the point that they have reduced relevance. Agents of interest could include Eastern Equine Encephalitis, underappreciated species of Babesia or filarial worms and Zika virus. In this changing landscape, blood operators need to become more agile as threats change and new ones emerge. This agility will enable blood operators to; identify and estimate the risks of these agents to the blood supply; reallocate resources to new risks and avoid unnecessary donor deferrals. 

Purpose: This session will; 1) pose key questions about participants views of emerging pathogens and their risks to the blood supply, 2) Identify known information about some potentially new threats, 3) compare risk mitigation strategies and decision-making approaches that could be applied to each of the identified agents, 5) engage participants on their concerns about the different emerging and “submerging” pathogens. 

Faculty:

  • Moderator Dr. Steven J Drews - short introduction of issues/problem, introduction of key session questions
  • Dr. Steven J Drews - “The changing epidemiology of arthropod-borne viruses in North America: are these agents a threat to the blood supply?” 
  • Dr. Evan Bloch - Associate Professor, Associate Director, Transfusion Medicine, Johns Hopkins University School of Medicine, Department of Pathology- “Vectors, protists and worms: What are the new threats to blood operators globally and how do they still impact North America?” 
  • Dr. Silvano Wendel – Diretor Médico, Banco de Sangue Medical Director, Blood Bank, Hospital Sirio Libanês, São Paulo, Brasil - “Zika virus risks to the blood supply in the Americas- Is this a submerging risk and can some operators move on?”

Learning Objectives:
  • Describe known information about at least one potentially new infectious diseases threats to the blood supply and information about at least one infectious disease threat to the blood supply that may be waning.
  • Debate risk mitigation strategies and decision-making approaches that could be applied to each of the identified emerging or submerging agents that participants learned about.
  • Propose appropriate approaches to respond to these or other relevant emerging/submerging infectious diseases threats to the blood supply in their geographic region.
Speaker(s): Disclosures
  • Steven Jeffrey Drews, PhD FCCM D(ABMM) : Consultant: Johnson & Johnson/Janssen
  • Evan Bloch, MD : Honoraria: Grifols, Terumo
  • Silvano Wendel, MD, PhD : Nothing to disclose
Standard: $25.00
Members: $20.00
Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content